Biotech Healthcare announced the launch in Europe of Bio-Hyalur LVD, a combination of cohesive and dispersive viscoelastic solution. It is a mix of hyaluronic acid (3%) and chondroitin sulfate (4%), enabling space maintenance and protection to endothelium, according to a company news release.
Bio-Hyalur LVD maintains the depth of the anterior chamber during the entire surgical procedure and permits greater operative precision without any risk of damaging the endothelium of cornea or other intraocular tissues. The visco elasticity of the solution maintains space and prevents flattening of the anterior chamber. Furthermore, its osmolarity and pH resembles the natural ophthalmic solution and hence post-operative quiet eyes, according to Biotech Healthcare.
The rheological and lubricating characteristics of Bio-Hyalur LVD are suitable to different phases of cataract surgery. It provides excellent visibility of the operating space.
Bio-Hyalur LVD is CE Mark approved.